Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In a study in Nature, Wang et al. describe how circadian rhythms can impact tumour suppression through their effects on dendritic cells, a finding that could help to optimize clinical trials of cancer immunotherapies.
Two recent studies have demonstrated how senescent cancer cells alter their cell surface proteome to induce anti-tumour immune responses, highlighting the potential therapeutic role of inducing senescence to improve anti-tumour immunity.
In this study, Cao et al. identified previously undiscovered metabolites produced by human gut microbes that cause DNA damage, and analysed their implication for colorectal cancer development.
Schmitt et al. describe an adaptive mechanism employed by colorectal cancers to handle pro-apoptotic chemotherapeutic insults, which could represent a targetable vulnerability with combination therapy.
Notarangelo et al. reveal that the oncometabolite d-2-hydroxyglutarate, which is released in high quantities by tumour cells, is taken up by CD8+ T cells in the tumour microenvironment and blocks their proliferation and cytotoxicity by inhibition of lactate dehydrogenase and metabolic reprogramming.
Social media has revolutionized health-care communication across medicine, particularly in the field of oncology. In this Comment, Manochakian and Dizon highlight the role of social media in promoting patient-driven cancer research to benefit all.
In two studies published concurrently, Dohlman et al. and Narunsky-Haziza et al. have found strong correlative links between the prevalence of fungal DNA and cancer.
In this Tools of the Trade article, Venkataramani describes the development of in vivo imaging workflows that allow the acquisition of imaging data with improved signal-to-noise matched to single-cell RNA-sequencing data.
Using single-cell RNA-seq and functional analysis in prostate cancer organoids and mouse models, Chan et al. identify inflammatory JAK–STAT signalling to drive the transition of adenocarcinomas to neuroendocrine prostate cancer.
Luo et al. uncover strong associations between the tumour microbiome and race, a finding that further emphasises the need for race diversity in cancer studies.
Wright et al. reveal how methotrexate binds to the human reduced folate carrier and outline key features that will aid the rational design of targeted antifolate therapeutics.
In this Tools of the Trade article, Luigi Ombrato describes the development of Cherry-niche, a cell labelling system, which enables the unbiased identification of cancer cell-neighbouring cells.
Ma et al. demonstrate that platelets suppress liver tumour growth in the context of non-alcoholic fatty liver disease through T cell-dependent antitumour immunity.
Xu, Yan et al. show that the hypothalamic–pituitary unit produces α-melanocyte-stimulating hormone in tumour-bearing mice, to promote myelopoiesis and immunosuppression.
In this Tools of the Trade article, Daniela S. Thommen describes the development and use of a patient-derived tumour fragment (PDTF) platform wherein surgically resected tumour lesions are cultured ex vivo, which enables patients’ responses to immunotherapy to be more faithfully modelled.
In two studies published concurrently, Pal et al. and Shi et al. reveal that certain gliomas rely on the de novo synthesis of pyrimidines. These studies go on to demonstrate the effectiveness of brain-penetrant inhibitors of de novo pyrimidine synthesis in preclinical models of glioma.
Chen et al. have developed a preclinical platform that enables the reprogramming of locoregional macrophages and microglia in situ with CD133-directed chimeric antigen receptors, which leads to the phagocytosis and removal of residual glioma stem cells after tumour debulking.
